Binding of urokinase to specific receptor sites on human breast cancer membranes. by Needham, G. K. et al.
r The Macmillan Press Ltd., 1987
Binding of urokinase to specific receptor sites on human breast cancer
membranes
G.K. Needham', G.V. Sherbet2, J.R. Farndon2 & A.L. Harris2
Depairtnient of Surgerv cmnid 2Caincer Research Unit, Uniiversity of Newcastle lupon Tyne, UK.
Summary The high molecular weight form of the plasminogen activator urokinase (54kD) binds to specific
receptor sites on the cell membrane of breast carcinomas by its inactive 'A' chain. The binding is of high
affinity (range of dissociation constants: 5.6 x 10-II to 4 x 10 -10 mol - and there were between 20 to
250fmol of binding sites per milligram of membrane protein) and equilibrium is reached in 60min. No
competition for binding sites was observed with eqpidermal growth factor, tissue plasminogen activator or the
low molecular weight form of urokinase (33 kD). Cross-linking experiments suggest that the receptor is a
monomeric unit of molecular weight of 50kD. This binding site provides a mechanism for the incorporation
of urokinase into the cell membrane.
Increased plasminogen activator secretion has been observed
in transformed and malignant cells and plasminogen
activator is thought to be involved in the processes of
invasion and metastasis (reviewed in Dano et al., 1985;
Mullins & Rohrlich, 1983; Saksela, 1985). Ossowski and
Reich (1983) showed that antibodies to urokinase type
plasminogen activator blocked tumour metastasis.
Plasminogen activator activity is concentrated in the cell
membrane fraction (Quigley, 1976) and its presence there
may enhance the migratory properties of cells. Recently, it
has been reported that monocytes possess receptors which
bind urokinase by its inactive 'A' chain thus leaving the
active site carried on the 'B' chain free to catalyse the
conversion of plasminogen to plasmin (Vassalli et al., 1985).
Urokinase is a serine protease and one of the two major
types of endogenous plasminogen activator. Urokinase is
secreted by numerous cell types in the form of a 54kD single
chain inactive proenzyme. It is converted to a two chain
54kD high molecular weight active form by limited
proteolysis and this can be degraded to an active 33kD or
low molecular weight form and a 17kD fragment from the
amino terminal end of the inactive 'A' chain (Stoppelli et al.,
1985).
Both types of plasminogen activator (tissue plasminogen
activator and urokinase) are found in breast tumours
(O'Grady et al., 1985) though only tissue plasminogen
activator secretion is induced by oestrogen in MCF-7 cells
(Ryan et al., 1984). The exact role of PA in neoplastic
processes is not yet known, but the close association between
raised PA levels and neoplasia is recognised. Plasminogen
activator activity is localised on the cell membrane and yet
may be found in solution in medium conditioned by tumour
cells. We have studied the binding of urokinase to membrane
preparations made from human breast carcinomas and
report the presence of receptors on 13 out of 29 tumours
which were studied.
Materials and methods
Human breast tumours and normal breast tissue were
collected fresh from the operating theatre and stored at
-20 C in sucrose glycerol HEPES buffer pH 7.4
(0.25 mol -i sucrose, 1.5 mmol 1- 1 magnesium chloride,
10mmoll-I HEPES in 50% glycerol).
Crude membrane preparations were made as follows:
tumour was trimmed of fat and diced in 10mmoll-1 Tris,
50mmol 1- NaCl buffer pH 7.4 at 4 C. Homogenisation by
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Ultra Turrax was performed and the resulting suspension
was centrifuged at lOOg for 10min. The supernatant was
removed and further spun at 100,000g for 45min. The pellet
of membrane was resuspended in buffer by glass/glass homo-
genisation and stored in aliquots at -20 C.
Human urinary urokinase of high and low mol. wt forms
was purchased from Calbiochem. Disuccinamidyl suberate
(DSS) was purchased from Pierce (UK) Ltd. Epidermal
growth factor (EGF) of receptor grade was purchased from
Sigma and two chain human melanoma tissue plasminogen
activator from Biopool, Box 4025, Umea, Sweden.
Radioiodination of urokinase was performed by the
method of Eaton and Baker (1983) and specific activity of
the product was typically 20 to 35uCitg- '.
Urokinase binding studies were carried out at 30 C in a
shaking water bath. Membrane protein (100,ug) was added
to 50pM radiolabelled urokinase in a total volume of 400,uI
Tris NaCl buffer pH 7.4 containing 2% acid treated bovine
serum albumin. Unlabelled urokinase was added in in-
creasing concentrations between 1 x 10 12 to 1 x 10 7 mol 1
the latter being the concentration used to estimate non-
specific binding. After incubation at 30 C for I h the reac-
tion was terminated by the addition of 1 ml of ice cold buffer
and the membrane pellet was spun down in a centrifuge at
14,000g for 5min. The counts bound were measured in a
gamma counter (Nuclear Enterprises NE1600). Each experi-
ment was performed in triplicate.
Urokinase binding was also studied in the presence of 1 ,IM
phenylmethylsulfonylfluoride (PMSF) which was sufficient to
quench all the enzymatic activity of the labelled urokinase.
Cross-linking of the receptor to labelled urokinase was
performed using DSS according to the method described by
Mukku and Stancel (1985). Polyacrylamide gel electro-
phoresis (SDS PAGE) was carried out using the system of
Laemmli (1974). Protein concentrations were measured by
the Lowry method.
Results
Specific binding of urokinase
Binding studies showed that there was specific binding of
54kD urokinase to breast cancer membranes. The time
course of binding (Figure 1) showed that equilibrium was
reached in 60 min, subsequent experiments were therefore
performed with a 60min incubation.
The addition of increasing concentrations of unlabelled
54kD urokinase reduced the amount of labelled urokinase
which bound specifically (Figure 2). The dissociation
constant was estimated at 4 x 10 -10 mmol 1 - from the
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concentration of unlabelled urokinase required to give half
maximal displacement.
From the Scatchard plot (Figure 2 inset), the Kd was esti-
mated as 2.7 x 10 -0moll- 1. The range of Kd in the seven
tumours found to have specific binding was from 6 x 10-I
to 4x 10- 10moll- with a mean of 2x 10- 10moll- . The
amount of urokinase bound ranged from 20-250fmolmg-'
of membrane protein with a mean value of 90 fmol mg- 1.
A third estimate of Kd was made by calculating the
association and dissociation rate constants K on and K off.
These were calculated from the slopes of the linearised plots
of the association and dissociation curves (insets Figures 1
and 3) and were 1.8x 108mol -Is-
I and 2x 10-2s-
I respec-
tively. Kd as estimated by K off/K on was 1.1 x 10- 0mol 1- 1.
Binding by two point competition assay
In addition to the 7 tumours described above, a further 22
were studied by a simplified two point competition assay in
which total binding was measured in the presence of 0.05 nm
labelled 54kD urokinase only and nonspecific binding was
taken to be the counts which bound in the presence of
100 nm unlabelled 54kD urokinase. Six of these showed
specific binding of between 5% and 14.6% of the total
counts added (mean 8.75%).
No specific binding was detected in 16 of the 29 tumours
studied or in the benign breast tissue tested (one fibro-
adenoma, one gynecomastia and two samples of normal
breast tissue taken from uninvolved sites near carcinomas.
Specificity of binding sites
The binding sites were specific for high mol. wt urokinase
since low mol. wt urokinase (differing from high mol. wt
urokinase only by the lack of the 17 kD amino terminal
fragment of the inactive 'A' chain), present in 1,000 fold
excess did not compete for binding (Figure 4a). When
labelled 33 kD urokinase was substituted for the labelled
54kD form, only nonspecific binding was observed (Figure
4b). This suggested that the inactive 'A' chain of urokinase
was essential for binding to occur. The presence of PMSF, a
specific active site inhibitor of the serine proteases, did not
affect binding (Figure 4c) suggesting that the active site on
the 'B' chain took no part in linkage to the receptor.
Epidermal growth factor is a peptide having 21% amino
acid sequence homology with part of the urokinase 'A' chain
Unlabelled 54kD urokinase molarity
Figure 2 A displacement curve of specifically bound (1251)
labelled 54kD urokinase by unlabelled 54 kD urokinase. The
. * . .--1 1-1- -1 1 *--C Inn* . r
90 amount ot- labelled 1igand which bound in the presence oi 1()(
nanmolar unlabelled 54kD urokinase was taken as representing
non-specific binding. Inset, Scatchard plot from which the
f time dissociation constant was calculated as 2.7 x 10 10 mol I
- I with
245 fmol receptor sites per milligram of membrane protein.
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Figure 3 Dissociation curve: Membrane was incubated with
50pM labelled urokinase for 60min until equilibrium was
reached. Unlabelled urokinase was then added to a concentration
of 50 nm and counts bound estimated at various time points.
Non-specific binding was determined at 3 time points (0, 90 and
300min) and this did not alter. Inset, linearised plot of
dissociation curve.
(Bachmann & Kruithof, 1984) and it seemed appropriate
therefore to look for competition between EGF and
urokinase for binding sites. There was no change in
urokinase binding in the presence of excess EGF. Tissue
plasminogen activator also has homologous regions to the
urokinase 'A' chain and its inactive chain and this too did
not compete for binding sites (Figure 4c).
Urokinase receptor molecular weight
An estimate of the receptor's mol. wt was made by cross-
linking the labelled 54kD urokinase to membrane
preparation using the bifunctional cross-linking agent DSS.
The solubilised membrane was run on a 7% SDS PAGE
(Figure 5a). Autoradiography of the dried gel was carried
out. Lanes I and 2 contained membrane incubated in the
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Figure 4 Competition for binding sites between labelled 33 kD
or 54kD urokinase and other peptides.
presence of I x 1010 urokinase. Lanes 3 and 4 contained
membrane incubated with labelled 54kD urokinase only. A
band representing specific binding was visible in lanes 3 and
4 at 107 kD in non-reducing conditions and this
corresponded to a mol. wt of 53kD for the receptor. The
receptor-urokinase complex appeared at 72.5kD in reducing
conditions (Figure 5b). Since urokinase is cleaved into 22kD
inactive 'A' and 33kD active 'B' chains in such conditions,
this was further evidence that it was the inactive 'A' chain
involved in binding.
Discussion
The existence of a urokinase binding site explains how
urokinase can exist both as a cell bound enzyme and also in
soluble form in the bloodstream, urine or secreted into
culture medium of cells in tissue culture. The plasma
urokinase level is I to 2 x 0-I0molI- and this is within
the range of the receptor's Kd (Vassalli et al., 1985).
Plasminogen activator has previously been measured in
human breast tumours but only in detergent solubilised or
Icytosol' extracts (Thorsen, 1982) and only recently have the
levels of each plasminogen activator been determined
separately. O'Grady et al. (1985) measured levels of
-72kD
- 33 kD
Figure 5 Autoradiograph of (a) non-reducing and (b) reducing
SDS PAGE of solubilised membrane after incubation with
labelled 54kD urokinase and DSS. Lanes I and 2: labelled 54kD
urokinase with 1,000 fold excess unlabelled 54 kD urokinase.
Lanes 3 and 4: labelled 54kD urokinase alone. Lanes I and 3:
150pg protein, lanes 2 and 4: 75 pg protein.
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plasminogcn activator in breast tumours and correlated a
high urokinase to tissue plasminogen activator ratio with
poor prognosis tumours such as chest wall recurrence and
tumours of an advanced stage whereas tissue plasminogen
activator was predominant in benign tumours and oestrogen
receptor positive cancers. We have found both types of
activator are present in human breast cancer membrane
preparations and the amount measured in cytosol is
relatively low (data not shown).
Localisation of plasminogen activator activity to the cell
mcmbrane firaction was demonstrated by Quigley (1976)
using normal and transformed fibroblasts. Ng et al. (1985)
measured plasminogen activators in rat breast adeno-
carcinoma membrane and showed that there were higher
levels in metastases than in primaries although the cytosolic
levels were similar.
Vassalli et al. (1985) demonstrated the existence of
receptors on human monocytes to which urokinase bound by
its inactive chain and retained its plasminogen activator
activity. Stoppelli et al. (1985) showed that the isolated
amino terminal fragment of the inactive chain of urokinase
with a mol. wt of 17 kD competed for the same binding sites.
No internalisation of the ligand occurred. The urokinase
bound to the receptor could be removed by gentle
trypsinisation and was therefore presumably on the outside
of the cell membrane.
Bajpai and Baker (1985) describe the uncovering of cryptic
binding sites on fibroblasts using acid treatment. It must be
presumed therefore that urokinase can only bind to
unoccupied receptors. The presence of unoccupied urokinase
binding sites in a proportion of breast cancers and their
absence from benign tumours and normal breast tissue is of
unknown significance as yet and we are currently studying
the relationship of urokinase binding to other biological
properties.
This phenomenon of a secreted protein binding to the cell
of origin is an example of an autocrine mechanism. The
resulting concentration of urokinase at the cell surface not
only localises activity to the immediate area around the cell
but also protects the active site of the enzyme from
inactivation by protease nexin (Baker et cl., 1986).
Binding of PA to cells has been described previously by
mechanisms other than urokinase receptors. Protease nexin I
binds urokinase by its active site and mediates its uptake
into cells by binding to a specific cell surface protease nexin
receptor thus inactivating the enzyme (Baker et al., 1980).
This differs from the mechanism described here in that the
availability of the active site is not preserved and a soluble
factor is involved. Tissue plasminogen activator was found
to bind to both live and fixed fibroblasts with preservation
of activity and with no soluble nexin type molecule
mediating the binding (Hoal et al., 1983). Since we found
tPA did not compete with urokinase for the urokinase
binding site, there was presumably another process involved.
Work by Del Rosso et al. (1985) showed urokinase
binding to 3T3 fibroblasts was apparently through the active
site region since it could be blocked by benzamidine, a
molecule which reversibly binds to the binding pocket of
trypsin-like enzymes. Conversely, Bajpai and Baker (1985)
have described urokinase receptors on normal human fibro-
blasts which have similar properties to those on monocytes
and breast cancer membranes.
Urokinase receptors were first found on monocytes, cells
which have a natural tendency to migrate through tissues.
The work described here is the first report of urokinase
receptors in human malignant tissue. The binding is
mediated by the non-catalytic chain of the enzyme and the
properties of the tumour receptor agree with the previously
published reports (Vassalli et al., 1985; Stoppelli et al.,
1985, 1986; Bajpai & Baker 1985a,b). The significance of
urokinase binding to cancer cell membrane by means of this
receptor may be seen as a mechanism by which cells can
acquire plasminogen activator on their surfaces which is
protected from inactivation by nexins and perhaps allows the
cells to develop migratory properties.
This work was funded by the North of England Cancer Research
Campaign.
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